| scholarly article | Q13442814 |
| P50 | author | Salim Abdool Karim | Q18161438 |
| Koleka Mlisana | Q46535610 | ||
| Penny Moore | Q55079169 | ||
| Elin S Gray | Q56637089 | ||
| Carolyn Williamson | Q70376235 | ||
| Lynn Morris | Q70377150 | ||
| Sengeziwe Sibeko | Q72617850 | ||
| Daniel J Sheward | Q89535080 | ||
| Nancy Tumba | Q114724304 | ||
| Molati Nonyane | Q114726171 | ||
| Maphuti C Madiga | Q114726172 | ||
| Tandile Hermanus | Q114726174 | ||
| Nthabeleng Ranchobe | Q114726187 | ||
| P2093 | author name string | Abraham Pinter | |
| William J Honnen | |||
| Zhong Lai | |||
| CAPRISA 002 Study | |||
| P2860 | cites work | Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies | Q24561905 |
| Structural definition of a conserved neutralization epitope on HIV-1 gp120 | Q24655948 | ||
| Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates | Q27489000 | ||
| Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1 | Q27662155 | ||
| Crystal Structure of PG16 and Chimeric Dissection with Somatically Related PG9: Structure-Function Analysis of Two Quaternary-Specific Antibodies That Effectively Neutralize HIV-1 | Q27662167 | ||
| Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B | Q28469023 | ||
| Antibody neutralization and escape by HIV-1 | Q29547345 | ||
| Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target | Q29547347 | ||
| Rapid evolution of the neutralizing antibody response to HIV type 1 infection | Q29618603 | ||
| Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies | Q29619015 | ||
| The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. | Q30367176 | ||
| Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models. | Q30369026 | ||
| Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization. | Q30423779 | ||
| Establishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection study | Q33328477 | ||
| Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection | Q33504604 | ||
| Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies | Q33614365 | ||
| Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressors | Q33725673 | ||
| High prevalence of neutralizing activity against multiple unrelated human immunodeficiency virus type 1 (HIV-1) subtype B variants in sera from HIV-1 subtype B-infected individuals: evidence for subtype-specific rather than strain-specific neutraliz | Q33920519 | ||
| A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals | Q34047445 | ||
| Infection by discordant strains of HIV-1 markedly enhances the neutralizing antibody response against heterologous virus | Q34120140 | ||
| Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. | Q34178201 | ||
| Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles | Q34406977 | ||
| The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter | Q34485260 | ||
| Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positio | Q34583767 | ||
| Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1 | Q34648079 | ||
| Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals | Q34962766 | ||
| Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa | Q35140032 | ||
| Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design | Q35196671 | ||
| Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors | Q35857221 | ||
| Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection | Q35857268 | ||
| The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection | Q36483346 | ||
| 4E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individual with an anti-membrane-proximal external region-neutralizing antibody response | Q36483956 | ||
| Rational modifications of HIV-1 envelope glycoproteins for immunogen design | Q36725263 | ||
| Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection | Q36845710 | ||
| Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. | Q36974754 | ||
| Prospects of HIV Env modification as an approach to HIV vaccine design | Q37017780 | ||
| Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection | Q37033294 | ||
| Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals | Q37033400 | ||
| Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm | Q37247974 | ||
| Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors | Q37333772 | ||
| Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression | Q37356036 | ||
| Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region | Q37410792 | ||
| Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens | Q37456354 | ||
| Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? | Q37519312 | ||
| Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIVSF162P4 | Q39610645 | ||
| Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies | Q43611862 | ||
| HIV vaccine design and the neutralizing antibody problem | Q46474020 | ||
| Cross‐Reactive Neutralizing Humoral Immunity Does Not Protect from HIV Type 1 Disease Progression | Q56886558 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | HIV | Q15787 |
| antibody | Q79460 | ||
| P304 | page(s) | 3128-3141 | |
| P577 | publication date | 2011-01-26 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop | |
| P478 | volume | 85 |
| Q26829865 | A Blueprint for HIV Vaccine Discovery |
| Q34478387 | A novel strategy for efficient production of anti-V3 human scFvs against HIV-1 clade C. |
| Q36171938 | A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies |
| Q34919985 | A twin-cysteine motif in the V2 region of gp120 is associated with SIV envelope trimer stabilization |
| Q92111662 | AAV-Mediated Expression of Broadly Neutralizing and Vaccine-like Antibodies Targeting the HIV-1 Envelope V2 Region |
| Q28485983 | Allosteric modulation of the HIV-1 gp120-gp41 association site by adjacent gp120 variable region 1 (V1) N-glycans linked to neutralization sensitivity |
| Q28545185 | An efficiently cleaved HIV-1 clade C Env selectively binds to neutralizing antibodies |
| Q35382871 | Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors |
| Q35641369 | Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency |
| Q39108751 | Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development |
| Q36692987 | Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. |
| Q39108710 | B-cell responses to HIV infection |
| Q38025633 | Basic research in HIV vaccinology is hampered by reductionist thinking |
| Q27675131 | Broad and potent neutralization of HIV-1 by a gp41-specific human antibody |
| Q33592852 | Broadly Neutralizing Antibodies as Treatment: Effects on Virus and Immune System |
| Q28073939 | Broadly Neutralizing Antibodies for HIV Eradication |
| Q35894094 | Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort |
| Q38065391 | Broadly neutralizing antibodies against HIV-1: templates for a vaccine |
| Q40055103 | Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge |
| Q98906656 | Broadly neutralizing plasma antibodies effective against autologous circulating viruses in infants with multivariant HIV-1 infection |
| Q34300812 | Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection |
| Q38631979 | Characterization of structural features and diversity of variable-region determinants of related quaternary epitopes recognized by human and rhesus macaque monoclonal antibodies possessing unusually potent neutralizing activities. |
| Q27644501 | Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus |
| Q35861256 | Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research |
| Q42933039 | Conference report: "Functional Glycomics in HIV Type 1 Vaccine Design" workshop report, Bethesda, Maryland, April 30-May 1, 2012. |
| Q36827348 | Conformation-dependent recognition of HIV gp120 by designed ankyrin repeat proteins provides access to novel HIV entry inhibitors |
| Q36694111 | Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop |
| Q36306344 | Contrasting antibody responses to intrasubtype superinfection with CRF02_AG. |
| Q34114798 | Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies |
| Q27684578 | Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization |
| Q36057328 | Design and characterization of a peptide mimotope of the HIV-1 gp120 bridging sheet |
| Q42207794 | Determinants in V2C2 region of HIV-1 clade C primary envelopes conferred altered neutralization susceptibilities to IgG1b12 and PG9 monoclonal antibodies in a context-dependent manner |
| Q89550864 | Development of Antibodies with Broad Neutralization Specificities against HIV-1 after Long Term SHIV Infection in Macaques |
| Q27022652 | Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection |
| Q58763247 | Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers |
| Q27644515 | Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies |
| Q38962226 | Distinct mechanisms regulate exposure of neutralizing epitopes in the V2 and V3 loops of HIV-1 envelope |
| Q36194234 | Diversification in the HIV-1 Envelope Hyper-variable Domains V2, V4, and V5 and Higher Probability of Transmitted/Founder Envelope Glycosylation Favor the Development of Heterologous Neutralization Breadth |
| Q34511092 | Elicitation of both anti HIV-1 Env humoral and cellular immunities by replicating vaccinia prime Sendai virus boost regimen and boosting by CD40Lm |
| Q50075362 | Envelope proteins of two HIV-1 clades induced different epitope-specific antibody response |
| Q35140508 | Estimated secondary structure propensities within V1/V2 region of HIV gp120 are an important global antibody neutralization sensitivity determinant |
| Q38756259 | Fragments of the V1/V2 domain of HIV-1 glycoprotein 120 engineered for improved binding to the broadly neutralizing PG9 antibody |
| Q27681527 | Functional Implications of the Binding Mode of a Human Conformation-Dependent V2 Monoclonal Antibody against HIV |
| Q35168642 | Functional characterization of two scFv-Fc antibodies from an HIV controller selected on soluble HIV-1 Env complexes: a neutralizing V3- and a trimer-specific gp41 antibody. |
| Q56913214 | HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes |
| Q21090490 | HIV-1 superinfection in women broadens and strengthens the neutralizing antibody response |
| Q28602877 | Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies |
| Q40296420 | Identification of Common Features in Prototype Broadly Neutralizing Antibodies to HIV Envelope V2 Apex to Facilitate Vaccine Design |
| Q34488183 | Identification of a new epitope for HIV-neutralizing antibodies in the gp41 membrane proximal external region by an Env-tailored phage display library |
| Q34455457 | Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models |
| Q47566053 | Identification of novel structural determinants in MW965 Env that regulate the neutralization phenotype and conformational masking potential of primary HIV-1 isolates |
| Q64269048 | Immune Correlates of Disease Progression in Linked HIV-1 Infection |
| Q89511484 | Immunogenicity of HIV-1 Vaccines Expressing Chimeric Envelope Glycoproteins on the Surface of Pr55 Gag Virus-Like Particles |
| Q34177732 | Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies |
| Q45324321 | Immunological and virological characteristics of human immunodeficiency virus type 1 superinfection: implications in vaccine design |
| Q38708708 | Improving the Expression and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers by Targeted Sequence Changes. |
| Q34298408 | Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2 |
| Q40159859 | Intrasubtype B HIV-1 Superinfection Correlates with Delayed Neutralizing Antibody Response |
| Q37370393 | Isolation of HIV-1-reactive antibodies using cell surface-expressed gp160Δc(BaL.). |
| Q36239578 | Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting |
| Q42241364 | Mitigation of variation observed in a peripheral blood mononuclear cell (PBMC) based HIV-1 neutralization assay by donor cell pooling |
| Q36978971 | Molecular evolution of the HIV-1 Thai epidemic between the time of RV144 immunogen selection to the execution of the vaccine efficacy trial |
| Q28728517 | Monoclonal Antibodies to the V2 Domain of MN-rgp120: Fine Mapping of Epitopes and Inhibition of α4β7 Binding |
| Q36760049 | Multiple pathways of escape from HIV broadly cross-neutralizing V2-dependent antibodies |
| Q34594978 | N332-Directed broadly neutralizing antibodies use diverse modes of HIV-1 recognition: inferences from heavy-light chain complementation of function |
| Q39206567 | Neutralization resistant HIV-1 primary isolates from antiretroviral naïve chronically infected children in India |
| Q37971867 | Neutralizing antibodies and control of HIV: moves and countermoves. |
| Q36246315 | Neutralizing antibody escape during HIV-1 mother-to-child transmission involves conformational masking of distal epitopes in envelope |
| Q36433894 | New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency |
| Q37668399 | Novel HIV vaccine strategies: overview and perspective |
| Q50617948 | Opening Fronts in HIV Vaccine Development: Tracking the development of broadly neutralizing antibodies |
| Q34309493 | Partial rescue of V1V2 mutant infectivity by HIV-1 cell-cell transmission supports the domain's exceptional capacity for sequence variation |
| Q47548910 | Phenotypic deficits in the HIV-1 envelope are associated with the maturation of a V2-directed broadly neutralizing antibody lineage. |
| Q24635002 | Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals |
| Q42230293 | Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines |
| Q64063774 | Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies |
| Q56892297 | Prime boost vaccination approaches with different conjugates of a new HIV-1 gp41 epitope encompassing the membrane proximal external region induce neutralizing antibodies in mice |
| Q37336704 | Robust neutralizing antibodies elicited by HIV-1 JRFL envelope glycoprotein trimers in nonhuman primates |
| Q38046828 | Role of human immunodeficiency virus type 1 envelope structure in the induction of broadly neutralizing antibodies. |
| Q35943521 | Selection Pressure on HIV-1 Envelope by Broadly Neutralizing Antibodies to the Conserved CD4-Binding Site |
| Q34116932 | Sequence-conserved and antibody-accessible sites in the V1V2 domain of HIV-1 gp120 envelope protein |
| Q34397758 | Sequences in Glycoprotein gp41, the CD4 Binding Site, and the V2 Domain Regulate Sensitivity and Resistance of HIV-1 to Broadly Neutralizing Antibodies |
| Q57295484 | Sequencing HIV-neutralizing antibody exons and introns reveals detailed aspects of lineage maturation |
| Q41876895 | Sequential Evolution and Escape from Neutralization of Simian Immunodeficiency Virus SIVsmE660 Clones in Rhesus Macaques |
| Q27723297 | Somatic Hypermutation-Induced Changes in the Structure and Dynamics of HIV-1 Broadly Neutralizing Antibodies |
| Q90335423 | Somatic hypermutation to counter a globally rare viral immunotype drove off-track antibodies in the CAP256-VRC26 HIV-1 V2-directed bNAb lineage |
| Q37554149 | Specific sequences commonly found in the V3 domain of HIV-1 subtype C isolates affect the overall conformation of native Env and induce a neutralization-resistant phenotype independent of V1/V2 masking |
| Q64228820 | Stabilization of the V2 loop improves the presentation of V2 loop-associated broadly neutralizing antibody epitopes on HIV-1 envelope trimers |
| Q55401174 | Structural and immunologic correlates of chemically stabilized HIV-1 envelope glycoproteins. |
| Q27644478 | Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9 |
| Q40043429 | Targeted N-glycan deletion at the receptor-binding site retains HIV Env NFL trimer integrity and accelerates the elicited antibody response |
| Q35686970 | The Broad Neutralizing Antibody Responses after HIV-1 Superinfection Are Not Dominated by Antibodies Directed to Epitopes Common in Single Infection |
| Q64281085 | The Chimpanzee SIV Envelope Trimer: Structure and Deployment as an HIV Vaccine Template |
| Q38243948 | The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development |
| Q34303849 | The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. |
| Q35076717 | The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection |
| Q37221499 | Tyrosine-sulfated V2 peptides inhibit HIV-1 infection via coreceptor mimicry. |
| Q34441935 | Unique C2V3 sequence in HIV-1 envelope obtained from broadly neutralizing plasma of a slow progressing patient conferred enhanced virus neutralization |
| Q38764543 | Use of broadly neutralizing antibodies for HIV-1 prevention |
| Q60959639 | V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity |
| Q92478519 | V2-Specific Antibodies in HIV-1 Vaccine Research and Natural Infection: Controllers or Surrogate Markers |
| Q35034268 | Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes |
| Q35077768 | Virological and immunological factors associated with HIV-1 differential disease progression in HLA-B 58:01-positive individuals |
| Q27025177 | Virological features associated with the development of broadly neutralizing antibodies to HIV-1 |
| Q40198060 | Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop |
Search more.